Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares insights into the Phase II CARDAMON trial (NCT02315716) which compared upfront autologous stem cell transplantation (autoSCT) versus carfilzomib-cyclophosphamide-dexamethasone (CarCyDex) consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.